Varubi Tablet
Product Images NDC 70720-101

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Varubi (NDC 70720-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tersera Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ter0b 0000 01

Chemical structure of rolapitant, the active ingredient in Varubi 90 mg oral tablets. The image depicts the molecular formula including the hydrochloride (HCl) and hydrate (H2O) components as part of the compound.*

FDA Label Image

Ter0b 0000 02

A bar chart comparing control and rolapitant groups, with the rolapitant group's data represented by filled gray bars. The chart likely depicts a measure related to the product Varubi, which contains rolapitant.*

FDA Label Image

Ter0b 0000 03

Bar graph depicting the percentage of patients experiencing no emesis (no vomiting) monitored across six treatment cycles comparing rolapitant at 90 mg to control. Each cycle is represented with paired bars for rolapitant and control, showing differences in no emesis rates over time.*

FDA Label Image

Ter0b 0000 04

A bar chart depicting the number of patients with nausea across different cycles (Control NT and Cycles 2, 3, 4, 5, 6) comparing Control and Rolapitant groups. The chart includes numeric data below each cycle showing patient counts and the difference percentage with confidence intervals for each cycle.*

FDA Label Image

Ter0b 0000 05

A bar chart illustrating the number of patients who received no emesis across multiple treatment cycles, comparing rolapitant 90 mg to control (Placebo). It displays data for Cycles 2 through 6, with the rolapitant group consistently showing higher numbers. The chart includes difference percentages and 95% confidence intervals for each cycle.*

FDA Label Image

Ter0b 0000 06

Packaging label for Varubi (rolapitant) tablets, 90 mg per tablet. The label indicates a single dose package containing two 90 mg tablets, totaling 180 mg. It is labeled Rx only for oral use, manufactured by TerSera Therapeutics LLC. The label includes storage instructions and child-resistant packaging information.*

FDA Label Image

Ter0b 0000 07

Varubi 90 mg oral tablet label section showing a QR code with placeholder text indicating lot number and expiration date. The label includes a blue border around the printed area and an outline of the tablet shape beneath the text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.